Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.57 |
| ▸ | TERT | O14746 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29920588 | 0.86 | MAPT (0.57) | MAPTMAPK1L3MBTL1HTTPOLB | |
| SCHEMBL15064233 | 0.84 | RAC1 (0.57) | MAPTMAPK1L3MBTL1HTTPOLB | |
| SCHEMBL7963446 | 0.80 | MAPT (0.57) | MAPTMAPK1L3MBTL1HTTPOLB | |
| SCHEMBL25179738 | 0.79 | NPSR1 (0.68) | MAPTMAPK1L3MBTL1HTTPOLB | |
| SCHEMBL2287907 | 0.76 | NPSR1 (0.63) | MAPTMAPK1L3MBTL1HTTPOLB | |
| SCHEMBL22650914 | 0.75 | RAC1 (0.51) | MAPTMAPK1L3MBTL1HTTPOLB | |
| SCHEMBL726764 | 0.74 | NPSR1 (0.59) | MAPTMAPK1HTTPOLBNPSR1 | |
| SCHEMBL20966313 | 0.73 | RAC1 (0.79) | MAPTMAPK1L3MBTL1HTTPOLB | |
| SCHEMBL2852620 | 0.72 | NPSR1 (0.67) | MAPTMAPK1HTTNPSR1MEN1 | |
| SCHEMBL11099191 | 0.72 | MAPT (0.70) | MAPTMAPK1L3MBTL1HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446299-B2 | Carbazole EHop-016 derivatives as anticancer and anti-migratory agents | UNIVERSITY OF PUERTO RICO (US) | 2022-09-20 | — | — | US | disclosed |
| US-11446299-B2 | Carbazole EHop-016 derivatives as anticancer and anti-migratory agents | UNIVERSITY OF PUERTO RICO (US) | 2022-09-20 | — | — | US | disclosed |
| US-20200352941-A1 | NOVEL CARBAZOLE EHOP-016 DERIVATIVES AS ANTI-CANCER AND ANTI-MIGRATORY AGENTS | UNIV PUERTO RICO (US) | 2020-11-12 | — | — | US | disclosed |
| US-20200352941-A1 | NOVEL CARBAZOLE EHOP-016 DERIVATIVES AS ANTI-CANCER AND ANTI-MIGRATORY AGENTS | UNIV PUERTO RICO (US) | 2020-11-12 | — | — | US | disclosed |
| US-10729689-B2 | Carbazole EHop-016 derivatives as anti-cancer and anti-migratory agents | UNIVERSITY OF PUERTO RICO (US) | 2020-08-04 | — | — | US | disclosed |
| US-10729689-B2 | Carbazole EHop-016 derivatives as anti-cancer and anti-migratory agents | UNIVERSITY OF PUERTO RICO (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190125746-A1 | NOVEL CARBAZOLE EHOP-016 DERIVATIVES AS ANTI-CANCER AND ANTI-MIGRATORY AGENTS | UNIVERSITY OF PUERTO RICO (PR) | 2019-05-02 | — | — | US | disclosed |
| US-20190125746-A1 | NOVEL CARBAZOLE EHOP-016 DERIVATIVES AS ANTI-CANCER AND ANTI-MIGRATORY AGENTS | UNIVERSITY OF PUERTO RICO (PR) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352941-A1 | NOVEL CARBAZOLE EHOP-016 DERIVATIVES AS ANTI-CANCER AND ANTI-MIGRATORY AGENTS | CDC42, ARHGEF2, ARHGDIB | MAPT 4054/4885MAPK1 395/4885L3MBTL1 2080/4885 |
| US-11446299-B2 | Carbazole EHop-016 derivatives as anticancer and anti-migratory agents | CDC42, ARHGEF2, HRAS | MAPT 3790/4885MAPK1 351/4885L3MBTL1 1891/4885 |
| US-20190125746-A1 | NOVEL CARBAZOLE EHOP-016 DERIVATIVES AS ANTI-CANCER AND ANTI-MIGRATORY AGENTS | CDC42, ARHGEF2, HRAS | MAPT 3896/4885MAPK1 482/4885L3MBTL1 1562/4885 |
| US-10729689-B2 | Carbazole EHop-016 derivatives as anti-cancer and anti-migratory agents | CDC42, ARHGEF2, GDI2 | MAPT 3908/4885MAPK1 393/4885L3MBTL1 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.